Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug530 | BNT162b1 Wiki | 0.58 |
| drug528 | BMS-986337 Placebo Wiki | 0.50 |
| drug3260 | Placebo microcrystalline methylcellulose Wiki | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3253 | Placebo for liposomed resveratrol and curcumin Wiki | 0.50 |
| drug2350 | Liposomed polyphenols resveratrol and curcumin Wiki | 0.50 |
| drug2218 | Isocaloric Diet Wiki | 0.50 |
| drug518 | BLZ945 Wiki | 0.50 |
| drug527 | BMS-986337 Wiki | 0.50 |
| drug1393 | Dutasteride 0.5 mg Wiki | 0.50 |
| drug531 | BNT162b2 Wiki | 0.50 |
| drug909 | Cannabis, Medical Wiki | 0.50 |
| drug1640 | Famotidine Wiki | 0.22 |
| drug3195 | Placebo Wiki | 0.06 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D000690 | Amyotrophic Lateral Sclerosis NIH | 1.00 |
| D016472 | Motor Neuron Disease NIH | 1.00 |
| D000070627 | Chronic Traumatic Encephalopathy NIH | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D005879 | Tourette Syndrome NIH | 0.50 |
| D001714 | Bipolar Disorder NIH | 0.35 |
| D012598 | Scoliosi NIH | 0.34 |
| D012640 | Seizures NIH | 0.29 |
| D006526 | Hepatitis C NIH | 0.29 |
| D000755 | Anemia, Sickle Cell NIH | 0.25 |
| D005356 | Fibromyalgia NIH | 0.22 |
| D001927 | Brain Diseases NIH | 0.20 |
| D000070642 | Brain Injuries, Traumatic NIH | 0.17 |
| D015212 | Inflammatory Bowel Diseases NIH | 0.17 |
| D010300 | Parkinsonian NIH | 0.15 |
| D001930 | Brain Injuries, NIH | 0.14 |
| D059350 | Chronic Pain NIH | 0.13 |
| D003424 | Crohn Disease NIH | 0.13 |
| D009103 | Multiple Sclerosis NIH | 0.11 |
| D040921 | Stress Disorders, Traumatic NIH | 0.09 |
| D014947 | Wounds and Injuries NIH | 0.08 |
| D013313 | Stress Disorders, Post-Traumatic NIH | 0.08 |
| D004194 | Disease NIH | 0.08 |
| D013577 | Syndrome NIH | 0.04 |
| D003141 | Communicable Diseases NIH | 0.03 |
| D007239 | Infection NIH | 0.02 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
| D018352 | Coronavirus Infections NIH | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0007354 | Amyotrophic lateral sclerosis HPO | 1.00 |
| HP:0100754 | Mania HPO | 0.35 |
| HP:0001250 | Seizure HPO | 0.22 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001298 | Encephalopathy HPO | 0.20 |
| HP:0002037 | Inflammation of the large intestine HPO | 0.17 |
| HP:0012532 | Chronic pain HPO | 0.13 |
| HP:0100280 | Crohn's disease HPO | 0.13 |
Navigate: Correlations HPO
There are 4 clinical trials
This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.
Description: Covid-19 infection rates in cannabis users will be compared to rates in the general population. Our online questionnaire responses will compare infection rates of cannabis users in this study against the Johns Hopkins University Coronavirus Research Center data (https://coronavirus.jhu.edu).
Measure: Prevention of COVID-19 Time: Five yearsDescription: Severity of persistent symptoms in cannabis users testing positive for active infection and/or antibodies will also be compared to the general population. Patients will answer the widely used FLU-PRO questionnaire, which asks about flu symptoms and severity, to capture diagnoses, symptoms, and medical interventions related to COVID-19. The data from cannabis user patients will be compared with national and international data surveys, such as the Covid Symptom Study (https://covid.joinzoe.com/us-2).
Measure: Treatment of COVID-19 Time: Five yearsDescription: The primary objective is to assess the efficacy and safety of medical cannabis as medicine for treatment of chronic pain and other chronic debilitating diseases. Pain will be measured by Brief Pain Inventory (BPI) numeric scale. Change from baseline in BPI will be assessed at 3-month intervals. For prospective associations between cannabis use and outcomes, use of a lagged mixed-effects models will examine temporal associations between cannabis use and pain severity, opioid sparing, and patient satisfaction. Data will be analyzed from baseline and the annual follow-up waves.
Measure: Treatment of Symptoms Time: Five yearsDescription: Secondary objectives include evaluating increases or decreases in quality of life, and increases or decreases in concomitant opioid use. Satisfaction with treatment will be measured by a Visual Analog Score (VAS). Change From baseline in Satisfaction with treatment measured by (VAS) be assessed at 3-month intervals.
Measure: Cannabis Impact on Quality of Life Time: Five yearsDescription: Tertiary objectives will examine preferences for routes of administration, and preferences for THC / CBD ratios. Categorical factors will be summarized using frequencies and percentages, while continuous measure distributions will be described using means, standard deviations, and quartiles of interest.
Measure: Cannabis Route and Dosing Time: Five yearsDescription: Incidence of Treatment-Related Adverse Events will be measured by Physician Global Assessment (PGA) numeric scale. Number of participants with Treatment-Related Adverse Events will be assessed by CTCAE v4.0.
Measure: Monitoring Adverse Events Time: Five yearsIt is an open label study to evaluate safety, tolerability and brain microglia response in participants with ALS following multiple doses of BLZ945.
Description: Volume of distribution (Vt) in different brain regions for each [11C]-PBR28 PET scan, and change after BLZ945 treatment, compared to baseline. Evaluate brain microglial reduction, as measured by reduction in TSPO binding following oral doses of BLZ945 in ALS participants by using PET imaging with [11C]-PBR28.
Measure: Change from baseline in volume of distribution (Vt) in different brain regions for [11C]-PBR28 PET scan Time: Day -42, up to Day 22Description: Measured by Cmax - The maximum plasma concentration of BLZ945
Measure: Plasma Pharmacokinetics (PK) of BLZ945 - Cmax Time: Day 1; up to Day 17Description: Measured by Tmax - Time to Reach the Maximum Concentration After Drug Administration of BLZ945
Measure: Plasma Pharmacokinetics (PK) of BLZ945 - Tmax Time: Day 1; up to Day 17Description: Measured by AUC - Area under the curve of BLZ945
Measure: Plasma Pharmacokinetics (PK) of BLZ945 - AUC Time: Day 1; up to Day 17Description: Measured by T1/2 - The elimination half-life of BLZ945
Measure: Plasma Pharmacokinetics (PK) of BLZ945 - T1/2 Time: Day 1; up to Day 17Description: Urine renal clearance (CLR) of BLZ945
Measure: Renal Clearance (CLR) of BLZ945 Time: Day 1; up to Day 7Description: To assess the CYP2C8 pharmacogenomic-pharmacokinetic relationship; CYP2C8 genotyping and BLZ945 plasma PK parameters
Measure: CYP2C8 genotyping and BLZ945 plasma PK parameters Time: Day 1; up to Day 17Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive and fatal neurodegenerative disease characterized by progressive weakness involving limb, bulbar, and respiratory muscles.There is currently no information suggesting how COVID-19 affects patients diagnosed with amyotrophic lateral sclerosis (ALS). This is especially important as respiratory compromise is common in ALS patients and can complicate the clinical course as COVID-19 could lead to respiratory failure and need for intubation. We intend that this registry will guide our understanding of how COVID-19 affects patients with ALS.
Description: Assessed through outcomes reporting ranging from recovered infections to patient death reported in a patient facing registry.
Measure: COVID-19 incidence and prevalence in the ALS population Time: Data will be collected through study completion, an average of 3 yearsAmyotrophic lateral sclerosis (ALS) is a disease of an inflammatory nature, which causes progressive muscle weakness associated with cognitive and behavioural disorders. Pathogenically, it is characterised by loss of oxidative control, excitotoxicity due to excess glutamate and intestinal dysbiosis. In the absence of curative treatment, the aim of the study is to assess the impact at a clinical level of the combination of liposomed polyphenols to improve their effectiveness, with the drug Dutasteride which shows great anti-ALS properties by Molecular Topology methodology. A prospective, longitudinal, mixed, analytical, experimental and double-blind study is proposed, with a population sample of 100 patients distributed randomly in 50 patients in the intervention group who will receive treatment for 6 months, and 50 patients in the control group who will receive a placebo for the same period. The assessment will be at time 0, and at 3 months and 6 months after treatment, with functional, cognitive and behavioural tests, and of the state of inflammation and oxidation; and at time 0 and 6 months, of the intestinal microbiota.
Description: Maximum value: 48 points; Means better outcome motor variables Minimum value: 0 points
Measure: Revised Amyotrophic Lateral Sclerosis Functional Rating Scale associated with ALS Time: Time 0Description: Maximum value: 48 points; Means better outcome motor variables Minimum value: 0 points
Measure: Revised Amyotrophic Lateral Sclerosis Functional Rating Scale associated with ALS Time: 3 monthsDescription: Maximum value: 48 points; Means better outcome motor variables Minimum value: 0 points
Measure: Revised Amyotrophic Lateral Sclerosis Functional Rating Scale associated with ALS Time: 6 monthsDescription: Motor Variables
Measure: Electromyography Time: Time 0Description: Motor Variables
Measure: Electromyography Time: 3 monthsDescription: Motor Variables
Measure: Electromyography Time: 6 monthsDescription: Motor Variables
Measure: Measurement of forced vital capacity Time: Time 0Description: Motor Variables
Measure: Measurement of forced vital capacity Time: 3 monthsDescription: Motor Variables
Measure: Measurement of forced vital capacity Time: 6 monthsDescription: Variables related to inflammation and oxidation
Measure: Quantitative measurement of plasma IL-6 and TNF-alpha. Time: Time 0Description: Variables related to inflammation and oxidation
Measure: Quantitative measurement of plasma IL-6 and TNF-alpha. Time: 3 monthsDescription: Variables related to inflammation and oxidation
Measure: Quantitative measurement of plasma IL-6 and TNF-alpha. Time: 6 monthsDescription: Variables related to inflammation and oxidation
Measure: Quantitative measurement of plasma PCR. Time: Time 0Description: Variables related to inflammation and oxidation
Measure: Quantitative measurement of plasma PCR. Time: 3 monthsDescription: Variables related to inflammation and oxidation
Measure: Quantitative measurement of plasma PCR. Time: 6 monthsDescription: Variables related to inflammation and oxidation
Measure: Quantitative measurement of plasma haptoglobin. Time: Time 0Description: Variables related to inflammation and oxidation
Measure: Quantitative measurement of plasma haptoglobin. Time: 3 monthsDescription: Variables related to inflammation and oxidation
Measure: Quantitative measurement of plasma haptoglobin. Time: 6 monthsDescription: Variables related to inflammation and oxidation
Measure: Quantitative measurement of TEAC (oxidation). Time: Time 0Description: Variables related to inflammation and oxidation
Measure: Quantitative measurement of TEAC (oxidation). Time: 3 monthsDescription: Variables related to inflammation and oxidation
Measure: Quantitative measurement of TEAC (oxidation). Time: 6 monthsDescription: Variables related to inflammation and oxidation
Measure: Quantitative measurement of plasma 8-oxoG. Time: Time 0Description: Variables related to inflammation and oxidation
Measure: Quantitative measurement of plasma 8-oxoG. Time: 3 monthsDescription: Variables related to inflammation and oxidation
Measure: Quantitative measurement of plasma 8-oxoG. Time: 6 monthsDescription: Variables related to inflammation and oxidation
Measure: Quantitative measurement of plasma MDA. Time: Time 0Description: Variables related to inflammation and oxidation
Measure: Quantitative measurement of plasma MDA. Time: 3 monthsDescription: Variables related to inflammation and oxidation
Measure: Quantitative measurement of plasma MDA. Time: 6 monthsDescription: Variable for cognitive and behavioural assesment Maximum value: 136 points; Means better outcome Minimum value: 0 points Includes a behavioural test to interview the care provider
Measure: Edinburgh Cognitive and Behavioral ALS Screen Time: Time 0Description: Variable for cognitive and behavioural assesment Maximum value: 136 points; Means better outcome Minimum value: 0 points Includes a behavioural test to interview the care provider
Measure: Edinburgh Cognitive and Behavioral ALS Screen Time: 3 monthsDescription: Variable for cognitive and behavioural assesment Maximum value: 136 points; Means better outcome Minimum value: 0 points Includes a behavioural test to interview the care provider
Measure: Edinburgh Cognitive and Behavioral ALS Screen Time: 6 monthsDescription: Variable for cognitive and behavioural assesment Maximum value: 18 points; Means better outcome 16-15 points means frontosubcortical deficit 13-12 points means frontosubcortical dementia Minimum value: 0 points Includes a behavioural test to interview the care provider
Measure: Frontal Assessment Battery Time: Time 0Description: Variable for cognitive and behavioural assesment Maximum value: 18 points; Means better outcome 16-15 points means frontosubcortical deficit 13-12 points means frontosubcortical dementia Minimum value: 0 points Includes a behavioural test to interview the care provider
Measure: Frontal Assessment Battery Time: 3 monthsDescription: Variable for cognitive and behavioural assesment Maximum value: 18 points; Means better outcome 16-15 points means frontosubcortical deficit 13-12 points means frontosubcortical dementia Minimum value: 0 points Includes a behavioural test to interview the care provider
Measure: Frontal Assessment Battery Time: 6 monthsDescription: A Clinical Intestinal Microbiome will be performed, which is an analysis of the bacterial microbiota present in the intestine, from a stool sample.
Measure: Variables related to the microbiota Time: Time 0Description: A Clinical Intestinal Microbiome will be performed, which is an analysis of the bacterial microbiota present in the intestine, from a stool sample.
Measure: Variables related to the microbiota Time: 6 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports